All Pharma News
Gannex`s Strategic Partner Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH

Gannex`s Strategic Partner Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH
PR NEWSWIRE
22 Jan 2024
Share Share
Gannex Announces Positive Results from Phase II Trial of Once-Daily ASC41 Tablet

Gannex Announces Positive Results from Phase II Trial of Once-Daily ASC41 Tablet
PR NEWSWIRE
02 Jan 2024
Share Share
Ascletis’ Gannex reports positive interim PhII NASH data

Ascletis’ Gannex reports positive interim PhII NASH data
Ayisha Sharma ENDPTS
02 Jan 2024
Share Share
Gannex posts data on NASH asset at center of trade secret row

Gannex posts data on NASH asset at center of trade secret row
Nick Paul Taylor FIERCE BIOTECH
02 Jan 2024
Share Share
Gannex Published Phase I Data of ASC42

Gannex Published Phase I Data of ASC42
PR NEWSWIRE
05 Nov 2023
Share Share
Gannex Announces the Completion of Patient Enrollment for PII Trial of ASC42

Gannex Announces the Completion of Patient Enrollment for PII Trial of ASC42
PR NEWSWIRE
19 Jul 2023
Share Share
NAFLD clinical trial activity catching up in Chin, lacks domestic participation

NAFLD clinical trial activity catching up in Chin, lacks domestic participation
INDIANPHARMAPOST
27 Dec 2022
Share Share
Gannex doses first participant in primary biliary cholangitis DDI study

Gannex doses first participant in primary biliary cholangitis DDI study
CLINICALTRIALSARENA
16 Aug 2022
Share Share
Gannex Begins Dosing in the U.S. Drug-Drug Interaction Study of ASC42

Gannex Begins Dosing in the U.S. Drug-Drug Interaction Study of ASC42
PRNEWSWIRE
15 Aug 2022
Share Share
Gannex Begins Dosing in Phase II Trial of ASC42 for Primary Biliary Cholangitis

Gannex Begins Dosing in Phase II Trial of ASC42 for Primary Biliary Cholangitis
PRNEWSWIRE
10 Apr 2022
Share Share